Recombinant Human Neprilysin Protein

重组人Neprilysin蛋白 | 重组人CD10蛋白 | 重组人脑啡肽酶蛋白

Atriopeptidase | CALLA | CALLAmembrane metallo-endopeptidase (neutral endopeptidase, enkephalinase) | CD10 antigen | CD10 | CD10) | CD10membrane metallo-endopeptidase variant 1 | Common acute lymphocytic leukemia antigen | DKFZp686O16152 | EC 3.4.24 | EC

rp183630-10μg

10μg

无动物源

≥95%(SDS-PAGE)

Neprilysin/CD10, also known as NEP and neutral endopeptidase 24.11, is a zinc metallopeptidase expressed at the cell surface of a variety of cells. The enzyme functions both as an endopeptidase with a thermolysin-like specificity and as a dipeptidylcarboxypeptidase. NEP has been shown to be involved in the degradation of enkephalins in the mammalian brain and the inactivation of circulating atrial natriuretic peptide. NEP has also been identified as the common acute lymphocytic leukemia antigen (CALLA), and is expressed on the surface of lymphocytes in some disease states. These and other observations have resulted in considerable interest in NEP as a target for analgesics and antihypertensive drugs. NEP is also a major degrading enzyme of amyloid beta peptide (Aβ) in the brain, indicating that down-regulation of NEP activity, which could be caused by aging, can contribute to the development of Alzheimer’s disease by promoting Aβ accumulation. Post-translational: Myristoylation is a determinant of membrane targeting. Glycosylation at Asn-628 is necessary both for surface expression and neutral endopeptidase activity.

Immobilized Recombinant Human Neprilysin Protein (rp183630) at 1.0 μg/mL can bind CD10 Mouse mAb (Ab093617) with the EC50 of 109.3 ng/mL.

重组表达

80.6 kDa

N-His

81.3-100.1 kDa, under reducing conditions; 81.3-100.1 kDa, under non-reducing conditions.

HEK293 Accession #: P08473 | HEK293

<1.0 EU/μg

人(Human)

52-750 aa

HHHHHHYDDGICKSSDCIKSAARLIQNMDATTEPCTDFFKYACGGWLKRNVIPETSSRYGNFDILRDELEVVLKDVLQEPKTEDIVAVQKAKALYRSCINESAIDSRGGEPLLKLLPDIYGWPVATENWEQKYGASWTAEKAIAQLNSKYGKKVLINLFVGTDDKNSVNHVIHIDQPRLGLPSRDYYECTGIYKEACTAYVDFMISVARLIRQEERLPIDENQLALEMNKVMELEKEIANATAKPEDRNDPMLLYNKMTLAQIQNNFSLEINGKPFSWLNFTNEIMSTVNISITNEEDVVVYAPEYLTKLKPILTKYSARDLQNLMSWRFIMDLVSSLSRTYKESRNAFRKALYGTTSETATWRRCANYVNGNMENAVGRLYVEAAFAGESKHVVEDLIAQIREVFIQTLDDLTWMDAETKKRAEEKALAIKERIGYPDDIVSNDNKLNNEYLELNYKEDEYFENIIQNLKFSQSKQLKKLREKVDKDEWISGAAVVNAFYSSGRNQIVFPAGILQPPFFSAQQSNSLNYGGIGMVIGHEITHGFDDNGRNFNKDGDLVDWWTQQSASNFKEQSQCMVYQYGNFSWDLAGGQHLNGINTLGENIADNGGLGQAYRAYQNYIKKNGEEKLLPGLDLNHKQLFFLNFAQVWCGTYRPEYAVNSIKTDVHSPGNFRIIGTLQNSAEFSEAFHCRKNSYMNPEKKCRVW

Yes

Yes